Travere Therapeutics
TVTX
TVTX
126 hedge funds and large institutions have $875M invested in Travere Therapeutics in 2016 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 36 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
126
Holders Change
+15
Holders Change %
+13.51%
% of All Funds
3.37%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
25
Increased
51
Reduced
36
Closed
10
Calls
$35.1M
Puts
$6.93M
Net Calls
+$28.1M
Net Calls Change
+$36.4M
Top Buyers
| 1 |
BC
Broadfin Capital
New York
|
+$18.1M |
| 2 |
SCM
Scopia Capital Management
New York
|
+$9.87M |
| 3 |
Millennium Management
New York
|
+$9.39M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$8.62M |
| 5 |
KCM
Kingdon Capital Management
New York
|
+$8.51M |
Top Sellers
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$23.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$21.8M |
| 3 |
PA
Perceptive Advisors
New York
|
-$18.6M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$14.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$11.5M |
